STOCK TITAN

electroCore to Participate in the LD Micro Main Event XVI Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
electroCore CEO to present at LD Micro Main Event XVI Conference
Positive
  • CEO's presentation at LD Micro Main Event XVI Conference could generate positive investor interest
Negative
  • None.

ROCKAWAY, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the LD Micro Main Event XVI Conference in Los Angeles, California from October 3 – 5, 2023.

LD Micro Main Event XVI:
Date: Tuesday, October 3, 2023
Time: 4:00 pm PDT
Event: Company presentation
Virtual viewers: Livestream

For more information regarding the conference and to register to watch the presentation live, please visit the conference page here.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com


ElectroCore Inc

NASDAQ:ECOR

ECOR Rankings

ECOR Latest News

ECOR Stock Data

Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Health Technology, Medical Specialties, Manufacturing, Electromedical and Electrotherapeutic Apparatus Manufacturing
United States

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.